Full Press Release Details
Accelerate Diagnostics
Names Juan Martin as Head of Europe, Middle East and Africa
TUCSON, Ariz., March 23, 2015 (GLOBE
NEWSWIRE) -- Accelerate Diagnostics, Inc., an in vitro diagnostics company dedicated to providing solutions for the global
challenge of antibiotic resistant organisms, announced today that it has named Juan Martin as Executive Vice President and Head
of Europe, Middle East and Africa (EMEA).
Martin brings an exceptional track
record of success in leading large, global healthcare diagnostics businesses. He joins Accelerate Diagnostics from Siemens, where
he serves as Senior Vice President, Siemens Healthcare Diagnostics for South West Europe and General Manager of Siemens Healthcare
France. In this role he is responsible for a business with over $800 million in revenue and more than 1500 employees. Previously,
Juan held a number of successively larger roles with Siemens and Dade Behring including General Manager of Greece and Turkey as
well as Vice President of France, Belgium, Luxembourg, Greece & Turkey. Martin began his career at Coopers and Lybrand as an
"We are delighted to welcome
Juan to the Accelerate team," said Lawrence Mehren, President and CEO of Accelerate Diagnostics. "With the upcoming
introduction of our ID/AST system in Europe, Juan's deep experience in this key region will be invaluable as we move to establish
leadership in the global clinical microbiology market."
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. (Nasdaq:
AXDX), is focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility
testing of infectious pathogens. The company's revolutionary ID/AST platform utilizes a proprietary process with both genomic
and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity.
For more information, visit www.acceleratediagnostics.com.
Forward-Looking Statements
This press release contains words
such as "expects," "shall," "will," "believes" and other similar expressions that
are intended to identify forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities
Litigation Reform Act of 1995. Such statements in this announcement are made based on the company's current beliefs, known
events and circumstances at the time of publication and, as such, are subject in the future to unforeseen risks and uncertainties
that could cause the company's results of operations, performance and achievements to differ materially from current expectations
expressed in, or implied by, these forward-looking statements. For a full discussion of the company's risks and uncertainties,
which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors"
in Item 1A in the company's Annual Report on Form 10-K, filed with the SEC on February 26, 2015. In addition, the company's
forward-looking statements could be affected by general industry and market conditions and growth rates. Except as required by
federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new
events, uncertainties or other contingencies.
Russell Public Communications
Blueprint Life Science Group
415.375.3340 Ext. 103